June 27, 2019June 27, 2019

Copiktra Induces Promising Clinical Activity in PTCL Patients, Phase 1 Trials Show

News

Copiktra (duvesilib) shows promising clinical activity in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), inducing responses in 44% to 57% of patients included in Phase 1 trials. The ... Read more

June 22, 2018

Duvelisib Effective in Relapsed or Refractory CLL/SLL Patients Who Failed Arzerra, Extension Study Shows

News

Patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who failed prior Arzerra (ofatumumab) treatment achieved robust and durable responses after switching to duvelisib, Verastem Oncology announced. Results from the Phase 3 crossover extension study IPI-145-12 (NCT02049515) ... Read more